The STXBP1 gene is associated with early infantile epileptic encephalopathy type 4 (EIEE4), a severe neurological disorder characterized by early-onset seizures and developmental delays. Genetic testing for mutations in the STXBP1 gene is crucial for diagnosing this condition, enabling early intervention and personalized management strategies for affected individuals.
DNA Labs UAE offers a comprehensive genetic test targeting the STXBP1 gene to identify mutations that may lead to EIEE4. The test is designed to provide accurate and reliable results, which are essential for the diagnosis and treatment planning of this epileptic encephalopathy. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the sophisticated technology employed.
By opting for this genetic test, families and healthcare providers can gain valuable insights into the genetic underpinnings of the condition, facilitating informed decisions about care and support for those affected by EIEE4.
The GUF1 gene is associated with early infantile epileptic encephalopathy type 40 (EIEE40), a severe form of epilepsy that emerges in the first months of life. This condition is characterized by frequent seizures that are resistant to treatment, developmental delays, and sometimes other neurological issues. Genetic testing for mutations in the GUF1 gene is crucial for diagnosing EIEE40, enabling targeted treatment plans and providing families with essential prognostic information.
At DNA Labs UAE, a specialized test is available for identifying mutations in the GUF1 gene that are linked to early infantile epileptic encephalopathy type 40. This test is an important tool for clinicians in the diagnosis and management of this challenging condition. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the GUF1 gene. By offering this test, DNA Labs UAE supports healthcare providers and families in the early detection and intervention of EIEE40, potentially improving outcomes for affected infants.
The GABRB1 gene plays a crucial role in the development and function of the central nervous system. Mutations in this gene are associated with early infantile epileptic encephalopathy type 45 (EIEE45), a severe form of epilepsy that manifests in the first few months of life. This condition is characterized by frequent seizures and significant developmental delays, affecting a child's cognitive and physical growth.
To diagnose this condition accurately, genetic testing for the GABRB1 gene is available at DNA Labs UAE. The test is designed to identify mutations in the GABRB1 gene that are linked to EIEE45, providing crucial information for the diagnosis, management, and treatment of affected individuals. The test cost is set at 4400 AED, reflecting the comprehensive analysis and detailed reporting that accompanies this specialized diagnostic service.
By opting for this genetic test, parents and healthcare providers can gain valuable insights into the condition, enabling early intervention strategies that can significantly improve the quality of life for those affected by EIEE45.
The GRIN2D gene plays a crucial role in the functioning of the nervous system, encoding a subunit of NMDA receptors that are involved in synaptic transmission and plasticity in the brain. Mutations in the GRIN2D gene have been associated with early infantile epileptic encephalopathy type 46 (EIEE46), a severe form of epilepsy that manifests in infancy. This condition is characterized by frequent seizures that are resistant to treatment, developmental delays, and other neurological issues.
To diagnose this genetic condition, DNA Labs UAE offers a specialized genetic test targeting the GRIN2D gene. The test is designed to identify mutations in the GRIN2D gene that are linked to EIEE46, providing crucial information for the diagnosis and management of the condition. Early diagnosis through genetic testing can help in managing the symptoms more effectively and can guide treatment decisions.
The cost of the GRIN2D gene test at DNA Labs UAE is 4400 AED. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the GRIN2D gene. Results from this test can provide valuable insights into the genetic basis of the patient's condition, aiding in the development of a personalized treatment plan.
Families with a history of EIEE46 or who have a child showing symptoms consistent with early infantile epileptic encephalopathy may consider this genetic test as part of their diagnostic journey. DNA Labs UAE ensures a comprehensive analysis, providing families and healthcare providers with critical information to support those affected by this challenging condition.
The FGF12 gene, associated with early infantile epileptic encephalopathy type 47 (EIEE47), plays a crucial role in the normal development and function of the nervous system. Mutations in the FGF12 gene can lead to severe neurological conditions characterized by early-onset seizures, developmental delays, and various other neurological abnormalities. Given the critical nature of timely and accurate diagnosis for managing such conditions, genetic testing for mutations in the FGF12 gene becomes indispensable.
DNA Labs UAE offers a specialized genetic test aimed at identifying mutations in the FGF12 gene to confirm a diagnosis of early infantile epileptic encephalopathy type 47. This test is particularly vital for families with a history of the condition or for infants presenting symptoms consistent with EIEE47. Early diagnosis through this genetic test can facilitate prompt intervention and management strategies, potentially improving outcomes and quality of life for affected individuals.
The cost of the FGF12 gene test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect any mutations in the FGF12 gene that could be indicative of EIEE47. Conducted in a state-of-the-art laboratory by experienced geneticists, the test adheres to stringent quality and accuracy standards, ensuring reliable results for patients and their families.
The SPTAN1 Gene Early Infantile Epileptic Encephalopathy Type 5 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at detecting mutations in the SPTAN1 gene. These mutations are associated with Early Infantile Epileptic Encephalopathy Type 5 (EIEE5), a rare but severe form of epilepsy that emerges in infancy. EIEE5 is characterized by frequent seizures, developmental delays, and various neurological impairments, making early diagnosis crucial for managing symptoms and improving quality of life.
This genetic test involves analyzing the patient's DNA to identify specific mutations in the SPTAN1 gene that are known to cause EIEE5. By pinpointing these mutations, healthcare providers can confirm a diagnosis of EIEE5, allowing for tailored treatment plans and genetic counseling for affected families.
The test is priced at 4400 AED and is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high accuracy and reliability of results. This test is particularly important for families with a history of EIEE5 or unexplained infantile seizures, as it provides essential genetic insights that can guide clinical decisions and support.
The SCN1A gene is critical in the proper functioning of brain cells, and mutations in this gene can lead to a range of epileptic disorders, including Early Infantile Epileptic Encephalopathy Type 6 (EIEE6). EIEE6 is a severe form of epilepsy that emerges in the first few months of life, characterized by frequent seizures and significant developmental delays. Genetic testing for mutations in the SCN1A gene is essential for diagnosing EIEE6, guiding treatment options, and providing information on the condition's prognosis.
DNA Labs UAE offers a specialized genetic test to identify mutations in the SCN1A gene associated with Early Infantile Epileptic Encephalopathy Type 6. This test is a vital tool for families seeking answers about this challenging condition. The cost of the SCN1A gene test at DNA Labs UAE is 4400 AED. By conducting this test, healthcare professionals can confirm the diagnosis of EIEE6, enabling them to tailor a treatment plan that can potentially improve the quality of life for affected infants and provide families with crucial information regarding the condition's management and outlook.
The CUX2 gene is implicated in early infantile epileptic encephalopathy type 67 (EIEE67), a severe form of epilepsy that manifests in infancy. This condition is characterized by frequent seizures and significant developmental delays, impacting the quality of life of affected individuals. Genetic testing for mutations in the CUX2 gene is crucial for the accurate diagnosis of EIEE67, enabling appropriate management and treatment strategies.
DNA Labs UAE offers a specialized genetic test for the CUX2 gene to identify mutations associated with early infantile epileptic encephalopathy type 67. The test is priced at 4400 AED and is conducted in a state-of-the-art laboratory setting by professionals who specialize in genetic diagnostics. This test is essential for families seeking answers to unexplained seizures in infants, providing them with critical information for medical decision-making and potential therapeutic interventions.
The KCNQ2 gene early infantile epileptic encephalopathy type 7 genetic test is a specialized diagnostic tool designed to identify mutations in the KCNQ2 gene, which are associated with early infantile epileptic encephalopathy type 7 (EIEE7). EIEE7 is a severe form of epilepsy that begins in the neonatal period or early infancy, characterized by frequent seizures and significant developmental delays. The KCNQ2 gene plays a crucial role in the proper function of potassium channels in the brain, which are essential for maintaining the electrical balance necessary for normal brain activity.
Conducted at DNA Labs UAE, this genetic test is pivotal for early diagnosis and intervention, offering insights into the specific genetic alterations responsible for the condition. By understanding the genetic basis of the disease, healthcare providers can tailor treatment plans more effectively, potentially improving outcomes for affected infants. The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed for mutations in the KCNQ2 gene.
The cost of the KCNQ2 gene early infantile epileptic encephalopathy type 7 genetic test at DNA Labs UAE is 4400 AED. While the test represents a significant investment, the information it provides can be invaluable for affected families, enabling access to targeted therapies and support services, and offering a clearer understanding of the condition's progression and prognosis.
The ARHGEF9 gene plays a critical role in the development and function of the nervous system. Mutations in this gene have been linked to early infantile epileptic encephalopathy type 8 (EIEE8), a severe form of epilepsy that emerges in infancy. This condition is characterized by frequent seizures and significant developmental delays, impacting the quality of life for affected individuals and their families.
To diagnose this condition accurately, genetic testing for mutations in the ARHGEF9 gene is available. DNA Labs UAE offers a comprehensive genetic test specifically designed to detect abnormalities in the ARHGEF9 gene, aiding in the diagnosis of early infantile epileptic encephalopathy type 8. The test is a crucial step in confirming the diagnosis, which can then guide treatment options and management strategies for the condition.
The cost of the ARHGEF9 gene test at DNA Labs UAE is 4400 AED. This investment in testing is vital for early diagnosis and intervention, potentially improving the prognosis for affected infants by allowing for tailored treatments that address the specific genetic mutation involved. Early and accurate diagnosis through genetic testing can also provide families with valuable information regarding the condition's inheritance patterns and risks for future pregnancies.
